TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06698328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transauricular Vagus Nerve Stimulation
Description: Mild non-invasive electrical stimulation to the vagus nerve using electrodes or stickers that adhere to the ear and the surrounding area.
Study: NCT05999721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Operating Room:~Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion.~Cardiothoracic Intensive Care Unit:~Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered.~Cardiothoracic ward:~The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered.
Study: NCT06327490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-guided manual lymphatic drainage
Description: Participants will perform manual lymphatic drainage on their affected arm using ICG lymphography images of the lymphatic pathway in their affected arm as guidance once daily for 2 years post-surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional manual lymphatic drainage
Description: Participants will perform manual lymphatic drainage on their affected arm using traditional technique once daily for 2 years post-surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: All participants will be injected with indocyanine green for lymphatic mapping of the affected upper extremity, however this mapping will only be used to guide manual lymphatic drainage for participants on the ICG-guided manual lymphatic drainage arm.
Study: NCT06398418

Intervention type: DRUG
Group type: OTHER
Intervention: R-5780
Description: Probiotic
Study: NCT06011252

Intervention type: DEVICE
Group type: OTHER
Intervention: Solia S lead with any BIOTRONIK Pacemaker
Description: * Name: Solia S lead with any BIOTRONIK Pacemaker~* Model: Solia S45/S53/S60~* Manufacturer: BIOTRONIK SE \& Co. KG~* Method of use: LBBAP implantation for all bradycardia indications.~* Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~* Device category and grade: E3610 Cardiovascular devices, Class III
Study: NCT05262673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific T cells CART/CTL and DCvac
Description: Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
Study: NCT05704244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999326
Description: 75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
Study: NCT06357078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Caregivers in the art therapy group will be given art therapy practices, lasting approximately 45 minutes-1 hour, twice a week for 4 weeks. Visual and handicraft practices (painting work, collage work, mandala work, painting with felt, clay work, painting and storytelling) are done in art therapy activities that will last for 4 weeks, and it is aimed to develop personal and emotional awareness, reduce stress and increase general well-being.
Study: NCT06310824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAB-22
Description: 60mg dose of a single subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia®
Description: 60mg dose of a single subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Prolia®
Description: 60mg dose of a single subcutaneous injection
Study: NCT06572449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: Specified dose on specified days
Study: NCT06640192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardised triple antiretroviral therapy
Description: patients have to use Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor. There are many types of drugs within this group, so they are not specified.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High doses Triple therapy antiretroviral drugs
Description: dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h
Study: NCT06651190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Caregiver Resource (PainCaRe)
Description: The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home. The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed. Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents. The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT. Please find attached the study protocol for reference.
Study: NCT06565546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin
Description: CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and Gabapentin: standard postoperative pain medications
Description: Participants will receive standard postoperative pain medications
Study: NCT05799625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StepOne Smartphone Application
Description: This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.
Study: NCT05179408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted-telerehabilitation
Description: Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/stept count; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)
Study: NCT06698328

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham non-invasive electrical stimulation using electrodes or stickers that adhere to the ear and the surrounding area.
Study: NCT06713369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib (AZD5305)
Description: PARP-inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AZD5305 microtracer
Description: IV radiolabeled microtracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AZD5305 (therapeutic dose)
Description: IV radiolabeled PARP inhibitor
Study: NCT05589181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Buprenorphine
Description: 32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Buprenorphine Dose
Description: 12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
Study: NCT05477680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation-guided surgery
Description: Surgeon removes brain lesions and assesses brain shift with neuronavigation
Study: NCT06098885

Intervention type: OTHER
Intervention: extraction orthodontic treatment
Description: bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
Study: NCT06691386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions
Study: NCT06336993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herbal compound
Description: patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
Study: NCT04686435

Intervention type: OTHER
Intervention: Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture
Description: Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
Study: NCT05239169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
Study: NCT06368076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: High intensity interval training on a bike or pedaltrainer from the wheelchair.
Study: NCT03249844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone + prednisolone
Description: The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),
Study: NCT06089395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiajian Guishen granules
Description: This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coenzyme Q10
Description: This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
Study: NCT06691386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions
Study: NCT05978791

Intervention type: PROCEDURE
Intervention: collection of venous blood or arterial blood
Description: 1. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~2. Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~3. Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~4. Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay).

Intervention type: PROCEDURE
Intervention: collection of venous blood or arterial blood
Description: 1. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~2. Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~3. Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~4. Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay).
Study: NCT05264207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing students' home-visit programme
Description: 12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~1. Self-care of chronic conditions and medication management~2. Healthy habits: physical activity and healthy eating~3. Access to social support resources~4. Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care from Public Andalusian Health Service
Description: Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care from Public Andalusian Health Service
Description: Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
Study: NCT05179122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical drain
Description: In this arm a surgical drain will be inserted prior to surgical wound closure
Study: NCT06718101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection
Study: NCT05461157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoperative silicone ointment
Description: The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative placebo ointment
Description: The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
Study: NCT06718101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) Injection
Study: NCT06720415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methadone, immediately prior to transport
Description: Patients will receive 0.4mg/kg PO methadone immediately prior to transport to the operating room

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous methadone
Description: Patients will receive 0.3mg/kg IV methadone after induction of general anesthesia
Study: NCT06720311

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Tubeless Super-Mini Percutaneous Nephrolithotomy
Description: Modified Tubeless Super-Mini Percutaneous Nephrolithotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Ureterorenoscopy
Description: Flexible Ureterorenoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave Lithotripsy
Description: Shockwave Lithotripsy
Study: NCT06719700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angio-immuno kinase inhibitor
Description: Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: PCI is recommended after the completion of chemoradiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Therapy with Toripalimab and Surufatinib
Description: Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.
Study: NCT06723639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A new two-layer surgical technique
Description: A new double row suturing technique attempting to restore the length of the distinct soleus and gastrocnemius portions of the Achilles tendon.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard non-surgical treatment
Description: Standard non-surgical treatment
Study: NCT06712147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Life's Hurdles: Mental health education
Description: The intervention group will cover educational topics around mental health including: mental health literacy, individual coping skills, stigma reduction strategies, resources for mental health support, and mental health rights.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Overcoming Life's Hurdles: Resources in the community
Description: The control group will cover topics including: mental health resources in the community, violence (i.e. domestic violence), employment and education opportunities, housing and tenant rights, immigration and acculturation, and community team building and empowerment.
Study: NCT06720714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Dose formulation: Solution for injection Route of administration: Subcutaneous infusion
Study: NCT06728072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin
Description: Metronidazole, ciprofloxacin, aspirin is initiated Cycle 1 Day 1 of chemotherapy. May be initiated any time from 7 days before Cycle 1 Day 1 up to and including Cycle 1 Day 3
Study: NCT06741072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dulbecco''s Phosphate-Buffered Saline
Description: Given SC